ARTICLE SUMMARY:
As Hologic’s turnaround success is increasingly recognized, the management team led by CEO Steve MacMillan is now setting its sights on long-term sustainability. Its key franchises are either stabilized or growing, some at surprising rates, even as headwinds keep the company vigilant.
Hologic Inc. was at a turning point in 2013. The provider of women’s health medical devices and diagnostics was losing money, two of its core product lines (representing 25% of revenues) had declining sales, and two of the nation’s leading shareholder activists, Carl Icahn and Relational Investors, which together owned 20% of the company, clamored for its break up.
